Among participants who had hepatitis C and who injected drugs, those treated at a non-stigmatizing “accessible care” treatment center co-located with a syringe service program (SSP) were nearly three times more likely to be cured of the infectious disease compared with those referred out to local clinicians through patient navigation, according to a randomized clinical trial led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, NYU Grossman School of Medicine, and the CUNY Graduate School of Public Health and Health Policy.
